Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Clinical evidence

VANQUISH-2

41 evidence topics · 16 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants per arm in the design poster
ArmPlanned participants
Placebo“n=306”
VK2735 7.5 mg“n=204”
VK2735 12.5 mg“n=306”
VK2735 17.5 mg“n=306”
Randomized participants per arm in the baseline poster
ArmRandomized participants
Placebo“N=276”
VK2735 7.5 mg“N=185”
VK2735 12.5 mg“N=276”
VK2735 17.5 mg“N=276”
Total“1013 participants were randomized from 127 U.S. study sites”
Description of analysis sets
Efficacy and safety analysis sets

No evidence found.

Results
Participant disposition
Baseline characteristics
Demographics and body size compared with NHANES
CharacteristicVANQUISH-2 (N=1013)NHANES
Age, mean (SD), years“58.3 (11.5)”“59.51 (11.7)”
Age 65 years or older“31%”“38%”
Sex, female to male, %“49:51”“49:51”
Weight, mean (SD), kg“105.3 (23.5)”“99.8 (20.2)”
Waist circumference, mean (SD), cm“118.2 (15.8)”“116.4 (12.6)”
BMI, mean (SD), kg/m2“37.1 (7.1)”“35.7 (6.2)”
BMI 27 to less than 30 kg/m2“13%”“22%”
BMI 30 to less than 35 kg/m2“32%”“34%”
BMI 35 to less than 40 kg/m2“26%”“22%”
BMI 40 kg/m2 or higher“29%”“22%”
Age distribution compared with NHANES
Age group, yearsVANQUISH-2 (N=1013)NHANES
18 to 34“3%”“5%”
35 to 44“11%”“8%”
45 to 54“22%”“16%”
55 to 64“34%”“33%”
65 to 74“25%”“26%”
75 or older“6%”“12%”
Race and ethnicity, prior GLP-1 receptor agonist exposure, and diabetes duration
CharacteristicVANQUISH-2 (N=1013)
Non-Hispanic White“43%”
Hispanic or Latino“29%”
Non-Hispanic Black“20%”
Non-Hispanic Asian“4%”
Other“3%”
Prior exposure to a GLP-1 receptor agonist“21%”
Time since type 2 diabetes diagnosis, mean (SD), years“10.3 (8.1)”
Baseline obesity complications compared with NHANES
ComplicationVANQUISH-2 (N=1013)NHANES
Hypertension“67%”“79%”
Dyslipidemia“66%”“89%”
Sleep apnea“25%”“NHANES comparator not available for sleep apnea.”
Osteoarthritis“22%”“31%”
Asthma“11%”“16%”
Coronary artery disease“8%”“17%”
Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: limitations evident from the available VANQUISH-2 documents

VANQUISH-2 is ongoing, with primary completion estimated for July 2027, data expected in the second half of 2027, and readout expected after VANQUISH-1, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, a congress abstract and poster authored by company employees, and a baseline poster authored by company employees and study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.

Enrollment fell short of the plan: the design poster planned approximately 1,122 participants (306 per arm and 204 in the 7.5 mg arm) and the initiation release targeted approximately 1100, while 1,013 participants were randomized (276 per arm and 185 in the 7.5 mg arm).

The 7.5 mg arm is the smallest, so estimates for that dose will be less precise. The trial enrolled adults with type 2 diabetes and HbA1c of 7% to 11% in the United States and Puerto Rico only; background therapy with DPP-4 inhibitors, amylin analogues, GLP-1 receptor agonists, and dual GLP-1/GIP receptor agonists was not permitted, while 21% of participants reported prior GLP-1 receptor agonist exposure. Participants had a mean BMI of 37.1 kg/m2 and a mean diabetes duration of 10.3 years, and the prevalence of obesity complications was lower than in the NHANES comparison population. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector, and in July 2026 the company stated that “almost everybody” in VANQUISH-2 was using the autoinjector. The extension study is expected to report in 2028 and will not inform the primary 78-week analysis.